aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States.
The last earnings update was 25 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
aTyr Pharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
aTyr Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
aTyr Pharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if aTyr Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
aTyr Pharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Sanjay S. Shukla, M.D., M.S., has been the Chief Executive Officer and President at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. from March 2016 to November 1, 2017. Dr. Shukla served as Vice President and Global Head of Integrated Medical Services for Novartis, he led global medical affairs operations, with oversight for all pharma general medicines therapies, both inline and in development. These included brands such as Gilenya, Cosentyx and Entresto. In addition, Dr. Shukla led the creation and development of the Real World Evidence Center for Excellence as well as incubating the Digital Strategy group within Global Medical Affairs. Previously, he served as Chief Executive Officer of RxMd, a clinical development consultancy that assisted in advancing proof of concept for early stage drug candidates. Prior to that, Dr. Shukla served in a variety of clinical development, data analytics and drug safety roles at Vifor Pharma and Aspreva Pharmaceuticals. He serves as a Member of Advisory Board at nPruv, Inc. and RxMD. Dr. Shukla received his M.D. from Howard University College of Medicine and his Bachelors of Science in Microbiology and Master of Science in Epidemiology and Biostatistics from the University of Maryland.
Sanjay's compensation has been consistent with company performance over the past year.
Sanjay's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the aTyr Pharma management team is less than 2 years, this suggests a new team.
CFO & Principal Accounting Officer
Strategic Advisor & Director
Senior Director of Investor Relations
General Counsel & Corporate Secretary
Executive Director of Biologics Development & Manufacturing
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the aTyr Pharma board of directors is about average.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD. The company has a collaboration with the University of Nebraska Medical Center for the development of neuropilin-2 receptor biology; and a research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases. The company was founded in 2005 and is headquartered in San Diego, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.